ABCG2 expression is related to low 5-ALA photodynamic diagnosis (PDD) efficacy and cancer stem cell phenotype, and suppression of ABCG2 improves the efficacy of PDD

PLoS One. 2019 May 13;14(5):e0216503. doi: 10.1371/journal.pone.0216503. eCollection 2019.

Abstract

Photodynamic diagnosis/therapy (PDD/PDT) are novel modalities for the diagnosis and treatment of cancer. The photosensitizer protoporphyrin IX is metabolized from 5-aminolevulinic acid (5-ALA) intracellularly, and PDD/PDT using 5-ALA have been approved in dermatologic malignancies and gliomas. However, the molecular mechanism that defines the efficacy of PDD/PDT is unknown. In this study, we analyzed the functions of ATP-binding cassette (ABC) transporters in PDD using 5-ALA. Most of the human gastrointestinal cancer line cells examined showed a homogenous staining pattern with 5-ALA, except for the pancreatic cancer line PANC-1, which showed heterogeneous staining. To analyze this heterogeneous staining pattern, single cell clones were established from PANC-1 cells and the expression of ABC transporters was assessed. Among the ABC transporter genes examined, ABCG2 showed an inverse correlation with the rate of 5-ALA-positive staining. PANC-1 clone #2 cells showed the highest level of ABCG2 expression and the lowest level of 5-ALA staining, with only a 0.6% positive rate. Knockdown of the ABCG2 gene by small interfering RNAs increased the positive rate of 5-ALA staining in PANC-1 wild-type and clone cells. Interestingly, PANC-1 clone #2 cells showed the high sphere-forming ability and tumor-formation ability, indicating that the cells contained high numbers of cancer stem cells (CSCs). Knockdown or inhibition of ABCG2 increased the rate of 5-ALA staining, but did not decrease sphere-forming ability. These results indicate that gastrointestinal cancer cell lines expressing high levels of ABCG2 are enriched with CSCs and show low rates of 5-ALA staining, but 5-ALA staining rates can be improved by inhibition of ABCG2.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily G, Member 2 / genetics*
  • Aminolevulinic Acid / pharmacology*
  • Animals
  • Cell Line, Tumor
  • Diketopiperazines / pharmacology
  • Female
  • Gastrointestinal Neoplasms / diagnosis
  • Gastrointestinal Neoplasms / genetics*
  • Gastrointestinal Neoplasms / metabolism
  • Gastrointestinal Neoplasms / therapy
  • Gene Expression Regulation, Neoplastic
  • Heterocyclic Compounds, 4 or More Rings / pharmacology
  • Humans
  • Mice
  • Neoplasm Proteins / genetics*
  • Neoplasm Transplantation
  • Neoplastic Stem Cells / metabolism*
  • Photosensitizing Agents / pharmacology*
  • Protoporphyrins / metabolism
  • Single-Cell Analysis
  • Up-Regulation

Substances

  • 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester
  • ABCG2 protein, human
  • ATP Binding Cassette Transporter, Subfamily G, Member 2
  • Diketopiperazines
  • Heterocyclic Compounds, 4 or More Rings
  • Neoplasm Proteins
  • Photosensitizing Agents
  • Protoporphyrins
  • Aminolevulinic Acid
  • protoporphyrin IX

Grants and funding

This work was supported by KAKENHI (15H04722 and 17H01540) (to Y.H. and T.T.) and the project for the Development of Innovative Research on Cancer Therapeutics from the Japan Agency for Medical Research and Development (16cm0106309h0001) (to T.T.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.